CAPRELSA DIN 02378590
Status: Marketed
Holder: SANOFI-AVENTIS CANADA INC
Health Canada record
| Active ingredient(s) | VANDETANIB 300 MG |
|---|
| Dosage form | Tablet |
|---|
| Route | Oral |
|---|
| Schedule | PRESCRIPTION |
|---|
| Class | Human |
|---|
| ATC | L01EX04 VANDETANIB |
|---|
| Original market date | 23-Feb-2012 |
|---|
| Current status date | 05-Apr-2024 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
sanofi-aventis Canada Inc. — licence 101470, currently licensed, last inspection rating C (2026-02-17).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing VANDETANIB
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02378582 | CAPRELSA | SANOFI-AVENTIS CANADA INC | Tablet | VANDETANIB 100 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 33018 | 2024-04-05 | New Drug Submission (NDS) | Administrative: Change in Product Ownership |
| 19274 | 2017-05-08 | Supplement to a New Drug Submission (SNDS) | SAFETY UPDATES TO THE PRODUCT MONOGRAPH IN RESPONSE TO AN ADVISEMENT LETTER PERTAINING TO NEW ADVERSE EVENTS |
| 18262 | 2016-07-08 | New Drug Submission (NDS) | TRANSFER OF DRUG IDENTIFICATION NUMBERS |
| 12921 | 2012-01-12 | New Drug Submission (NDS) | |
Request a quote for CAPRELSA
How to read a Canadian DIN record